Rifampicin

Generic Name: Rifampicin

Brand Names: Isonarif, Rifadin, Rifamate, Rifater, Rofact

Drug Type: Small Molecule

Chemical Formula: C_₄₃H_₅₈N_₄O_₁₂

CAS Number: 13292-46-1

Unique Ingredient Identifier: VJT6J7R4TR

Background: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)

Indication: Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.

Associated Conditions: Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis

Associated Therapies: Antibacterial therapy

Clinical Trials

A Study to Assess the Effect of Rifampin on the Pharmacokinetics of PCI-32765 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: PCI-32765
Drug: Rifampin

First Posted Date: 2013-01-08

Last Posted Date: 2013-04-17

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 18

Registration Number: NCT01763021

Identification and Evaluation of Endogenous Markers for the Assessment of CYP3A Activity

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Midazolam
Drug: Ketoconazole
Drug: Rifampicin

First Posted Date: 2013-01-04

Last Posted Date: 2014-05-26

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 16

Registration Number: NCT01760642

Locations: 🇰🇷
Seoul National Universtiy Hospital, Seoul, Korea, Republic of

Efficacy and Safety Study of Antibiotic Treatment to Treat Hip Prosthetic Joint Infection

Phase 2

Conditions: Hip Prosthetic Joint Infection

Interventions: Drug: VANCOMYCIN
Drug: CEFTRIAXONE
Drug: LINEZOLID
Drug: CLINDAMYCIN
Drug: SULFAMETHOXAZOLE AND TRIMETHOPRIM (CO-TRIMOXAZOLE)
Drug: FLUOROQUINOLONE
Drug: RIFAMPIN

First Posted Date: 2012-12-28

Last Posted Date: 2014-05-28

Lead Sponsor: University Hospital, Tours

Target Recruit Count: 100

Registration Number: NCT01757236

Locations: 🇫🇷
CHRU de Tours, Tours, Indre et Loire, France
🇮🇹
Azienda Opedaliera Universitaria San Maria della Misericordia, Udine, Italy
🇫🇷
CHU de Nantes, Nantes, France

and more 6 locations

Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection

Phase 2

Terminated

Conditions: Prosthetic Joint Infections of Knee
Infected Spacers
Prosthetic Joint Infections of Hip

Interventions: Drug: CEM-102
Drug: IV or Oral standard of care antibiotics
Drug: Rifampin

First Posted Date: 2012-12-28

Last Posted Date: 2019-04-19

Lead Sponsor: Arrevus Inc.

Target Recruit Count: 14

Registration Number: NCT01756924

The Effect of PXR Activation on Blood Pressure Regulation

Phase 4

Completed

Conditions: Blood Pressure Regulation

Interventions: Drug: Placebo
Drug: Rifampicin

First Posted Date: 2012-09-21

Last Posted Date: 2014-12-30

Lead Sponsor: University of Oulu

Target Recruit Count: 22

Registration Number: NCT01690104

Locations: 🇫🇮
Oulu University Hospital, Oulu, Finland

A Study to Investigate the Effects of Rifampicin on the Pharmacokinetics of Aleglitazar in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: aleglitazar
Drug: rifampicin

First Posted Date: 2012-09-06

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 24

Registration Number: NCT01679639

A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Abiraterone in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Abiraterone acetate
Drug: Rifampicin

First Posted Date: 2012-08-01

Last Posted Date: 2013-01-10

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 19

Registration Number: NCT01655147

Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: tasimelteon
Drug: Rifampin
Drug: Ketoconazole

First Posted Date: 2012-07-11

Last Posted Date: 2014-02-17

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 48

Registration Number: NCT01637636

Locations: 🇺🇸
QPS Bio-Kinetic Clinical Applications, Springfield, Missouri, United States

Drug-interaction Trial in Healthy Subjects With Oral Administration of Empagliflozin (BI 10773), Rifampicin and Probenecid

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Probenecid
Drug: Empagliflozin (BI 10773)
Drug: Empagliflozin
Drug: Rifampicin

First Posted Date: 2012-07-06

Last Posted Date: 2014-07-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT01634100

Locations: 🇩🇪
1245.83.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV

Phase 2

Terminated

Conditions: HIV Infection
Tuberculosis

Interventions: Drug: Standard-dose Lopinavir/Ritonavir
Drug: Double-dose Lopinavir/Ritonavir
Drug: Raltegravir
Drug: Isoniazid
Drug: Pyridoxine
Drug: Pyrazinamide
Drug: Ethambutol
Drug: Rifampin
Drug: Rifabutin

First Posted Date: 2012-05-18

Last Posted Date: 2018-02-13

Lead Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Target Recruit Count: 71

Registration Number: NCT01601626

Locations: 🇵🇪
Asociacion Civil Impacta Salud y Educacion - Miraf CRS (11301), Lima, Peru
🇧🇷
Instituto de Pesquisa Clinica Evandro Chagas (12101), Rio de Janeiro, Brazil
🇭🇹
Les Centres GHESKIO CRS (30022), Port-au-Prince, Haiti

and more 6 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy